Avecho Biotechnology (ASX:AVE) announced a milestone in its clinical development program, completing recruitment for the interim analysis cohort in its pivotal Phase 3 trial evaluating a TPM-enhanced cannabidiol capsule for treating insomnia.
According to the release, the company has enrolled approximately 210 participants required for this crucial check-in.
The interim analysis is designed to provide the first indication of the product's efficacy, de-risk the program moving forward, and confirm the exact number of participants required to complete the trial.
"Interim analysis results anticipated in June – a major value-defining milestone for Avecho's pivotal Phase 3 insomnia program," the company stated in its highlights.
The study aims to support the registration of the CBD capsule with the Therapeutic Goods Administration, targeting the unique Australian over-the-counter pathway.